The average P/S ratio for SMMT's competitors is 299.37, providing a benchmark for relative valuation. Summit Therapeutics Inc Corp (SMMT) exhibits a P/S ratio of 1752.23, which is 485.30% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.